



Introduction: The collected and shipped blood samples are exposed to a various extra-analytical factors prior to analysis. The aim of the study was 
to determine the stability of analytes in serum gel tubes and plain tubes exposed to a range of storage temperatures and times after centrifugati-
on.
Materials and methods: Fifteen healthy volunteers were recruited and venous blood was collected into four tubes, two with and two without 
gel separator. Analyzing the baseline samples in 30 min, all were stored at 4ºC or 24ºC for 6, 12, 18, 24, 30, 36, 48 and 72 hours and 1 week. Sixteen 
biochemical anaytes were measured on each sample. Variations remained under the desirable bias considered as clinically insignifi cant.
Results: On day three, most analytes remained stable including albumin, protein, creatinine, cholesterol, triglycerides, gamma-glutamyl transfe-
rase (GGT), alkaline phosphatase (ALP), alanine aminotransferase (ALT), creatine kinase (CK), lactate dehydrogenase (LD) regardless of tube types. 
Glucose concentration decreased markedly (P = 0.001) beginning from the fi rst hours of storage in plain serum. The stability maximized for the 
analytes including glucose, total bilirubin, urea nitrogen (BUN), uric acid stored at 4 ºC in gel tubes. Aspartate aminotransferase (AST) activity incre-
ased signifi cantly (P = 0.002) up to 48-h, however bias was not signifi cant clinically. High density lipoprotein (HDL) concentration was stable in gel 
tubes at 24 ºC, in plain tubes at 4 ºC stored up to 36-h.
Conclusion: Serum gel or non-gel tubes might be used interchangeably for 11 analytes chilled or at 24 ºC, whereas some restrictions must be appli-
ed for glucose, AST, BUN, HDL, and uric acid.
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Collecting blood samples from individual labora-
tories and studying in one center has become 
more popular in recent years to ease health care 
costs. Accordingly, the extra-analytical factors af-
fecting the analysis process such as diff erent trans-
portation conditions, prolonged storage at high or 
low temperature, improper handling (without fro-
zen packs), are still sources of interest (1,2). Though 
it is highly recommended to study tests from fresh-
ly drawn serum or plasma, delay in the testing pro-
cess or reuse of the samples for missing results 
that may cause false concentrations are sometimes 
inevitable (3-5).
For many years the blood collection tubes have 
been used both with and without gel separator. 
During centrifugation, gel undergoes a temporary 
change in viscosity and lodges between the 
packed cells and the top serum layer. Advantages 
of separator tubes are rapid separation of serum 
from cellular constituents of blood, easy transpor-
tation, elimination the need of aliquoting serum, 
and reduction the aerosolization of hazardous 
substances (6).
However, blood collection tube additives also can 
be a source of analytical errors. Inorganic silicates, 
or ellagic acid, thrombin and tromboplastin are 
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frequently used clot activators. Occasionally, clot 
activator particles may not pellet completely with 
the clot and may remain in the serum layer, caus-
ing interferences by coating pipetting devices es-
pecially during storage of the collection tube with 
improper storage temperatures (7,8).
While interference mechanism of the tube compo-
nents may be due to additives; where the interfer-
ing substance is present in the tube, chemical inhi-
bition or activation in the assay by tube compo-
nents, it is recommended to test tube component 
interference by collecting samples either at plain 
tubes and tubes with additives (9).
The information available for sample stability is in-
complete and confusing, especially after pro-
longed contact of sera with clot or gel. Most of the 
studies were designed by assessing the stability of 
parameters prior to centrifugation or with whole 
blood stored for a few days. The main objective of 
our study was to evaluate whether the separator 
gel or clot in tubes infl uence the concentrations of 
16 selected parameters in a clinically signifi cant 
way. To mimic the delays in processing or shipping 
in the diff erent tube types, we focused on four 
preanalytical conditions; a delay in processing of 
plain serum at 4 ºC, and at 24 ºC, and a delay in 
processing of serum in gel tube at 4 ºC, and at 24 
ºC up to one week of storage in ten time intervals. 
This study may help to verify the optimum stabili-




This experimental study was carried out in March 
2010. The study group consisted of fi fteen volun-
tary physicians and laboratory technicians (9 fe-
males and 6 males, age range 24-45 years), who 
gave written informed consent form for testing. 
The procedures we used were in accordance with 
the guidelines of the Helsinki Declaration on hu-
man experimentation.
Blood sampling
Blood was collected by using Vacuette® Standard 
tube holder and Vacuette® 21-gauge, 0.80 × 38 mm 
multisample needle (Vacuette, Greiner Bio-One, 
Kremsmünster, Austria).
Blood specimens were drawn into following types 
of plastic tubes: Vacuette® Tube Serum No Gel 9 
mL (Ref. No. 455092) (Serum Plain) and Vacuette® 
Tube Serum Gel Separator 8 mL (Ref. No. 455071) 
(Serum Gel).
Fasting venous blood was randomly collected in 
the morning from each participant by a single ve-
nipuncture to control for any draw order bias and 
the tubes were fi lled completely. Blood (totally, 34 
mL) was collected from each volunteer using two 
serum separator tubes with gel and two without 
gel. All were categorized according to tube types 
and storage temperatures:
Group I (N = 15) Serum Gel at 24 ºC (room tem-• 
perature defi ned as RT);
Group II (N = 15) Serum Gel at 4 ºC (chilled);• 
Group III (N = 15) Serum Plain at 24 ºC;• 
Group IV (N = 15) Serum Plain at 4 ºC.• 
Sera were allowed to clot for 30 min at RT and then 
centrifuged at 2200 x g for 10 min. Immediately 
following centrifugation, all specimens were ana-
lyzed within 30-min to obtain the “0 hours = T0” 
(baseline) values. Tubes of each group were then 
stored at particular storage temperatures (RT or 
chilled) and analyzed at diff erent time intervals (6-, 
12-, 18-, 24-, 30-, 36-, 48-, 72-hour and 1 week). To 
evaluate the stability of analytes in serum separa-
tor tubes, sera were stored on the gel or on the 
clot during the process. The tubes were kept avoid-
ing from light exposure at RT or chilled during all 
storage times up to one week. To avoid evapora-
tion, sample tubes were kept closed until analysis.
Methods
The following analytes were studied:
metabolites: glucose, total bilirubin, creatinine, • 
BUN, uric acid;
proteins: total protein, albumin;• 
lipids: triglycerides, cholesterol, HDL;• 
enzymes: ALP, ALT, AST, CK, GGT, and LD.• 
All assays were performed on the Abbott Aeroset 
(Abbott, Wiesbaden, Germany), according to the 
manufacturer’s specifi cations by using proprietary 
reagents at the Department of Biochemistry Labo-
ratory of Ataturk Training and Research Hospital in 
Izmir, Turkey.
Intra-assay analytical CV’s were determined by two 
levels of control materials (Bio-Rad Laboratories, 
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Milano, Italy) (N = 10, from each level on the same 
plate) on the same day before biochemical analy-
sis (Table 1). Additionally, for accuracy and internal 
quality check, two levels of control materials and 
the test samples were assayed in the same analyti-
cal run at each assay point during the process. All 
values of QC samples for analytes were within ± 2 
SD (standard deviation) of their respective target 
means during the entire investigation.
Statistical analysis
In the current study, to determine time dependent 
changes, the median from all 15 volunteers for 
each analyte was obtained for each time interval 
at each group. Statistically signifi cant changes 
were determined by non-parametric Friedman 
test for repeated-measures to examine the infl u-
ence of storage time. Finding the signifi cant diff er-
ences (P < 0.05), Wilcoxon signed-rank test was 
used for those groups. Post-hoc analysis was con-
ducted with a Bonferroni correction applied, re-
sulting in a signifi cance level set at P < 0.006 (0.05/9 
= 0.0055). All statistical analyses were performed 
using SPSS for Windows, version 15.0 (SPSS Inc., 
Chicago, IL, USA). To determine the clinically signif-
icant variations the percentage relative bias from 
the baseline sample was calculated by the formu-
la:
[(Cx-C1)/C1)] × 100.
C1: the median result of the T0 sample (N = 15),
Cx: the median result of the stored sample (N = 
15).
Percentage relative bias for paired groups (T0-T6, 
T0-T12, T0-T18, etc.) was then compared with the 
current analytical quality specifi cations for desir-
able bias taken from the Westgard QC (10), which 
was first published at 1999 and updated at 2012 by 
Ricos et al.
Results
The results of the present investigation at T0 are 
presented in Table 2 along with the reference in-
tervals for each analyte.
The statistical analysis of serum gel / clot contact 
time and temperature eff ects is presented in Table 
3. The tests that were suitable for analysis on the 
third day of storage in all groups were cholesterol, 
triglycerides, creatinine, CK, ALP, ALT, GGT LD 
Analyte CV 1 (%) Level 1 CV 2 (%) Level 2
Alanine aminotransferase (U/L) 1.5 37 0.7 110
Albumin (g/L) 1.8 39.8 2.0 23.7
Alkaline phosphatase (U/L) 2.1 93 0.4 415
Aspartate aminotransferase (U/L) 2.1 37 0.5 186
Bilirubin (total) (µmol/L) 1.5 17.7 0.5 90
Cholesterol (mmol/L) 0.6 6.84 0.6 2.59
Creatinine (µmol/L) 2.2 181 0.7 539
Creatine kinase (U/L) 0.9 135 0.3 431
Glucose (mmol/L) 0.4 5 0.7 16.5
Gamma -glutamyl transferase (U/L) 0.7 61.2 0.5 156
HDL-cholesterol (mmol/L) 3.3 1.89 5.3 0.81
Lactate dehydrogenase (U/L) 1.0 202 0.8 372
Protein (total) (g/L) 0.6 67.8 1.3 43.3
Triglyceride (mmol/L) 0.4 2.07 1.0 0.95
Urea nitrogen (mmol/L) 0.0 5.36 1.6 16.83
Uric acid (µmol/L) 0.8 302 0.8 592
For CV measurement, 10 samples were assayed on each level on the same plate.
TABLE 1. Intra-assay coeffi  cient of variations determined at two levels (Level 1 and 2).
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Analyte Method Median (IQR) Reference interval*
Alanine aminotransferase (U/L) UV without P5P 15 (9-65) 3-44
Albumin (g/L) Bromcresol green 44 (40-48) 35-52§
Alkaline phosphatase (U/L) PNPP 69 (37-135) 44-134
Aspartate aminotransferase (U/L) UV without P5P 14 (8-31) 10-32
Bilirubin (total) (µmol/L) Diazonium ion 10.9 (6.3-56.8) 5-21§
Cholesterol (mmol/L) CHOD-PAP 4.44 (3.52-6.92) 3.13-6.97
Creatinine (µmol/L) Alkaline picrate 71 (44-97) 56-101
Creatine kinase (U/L) UV-NAC activated 84 (27-170) ≤ 145§
Glucose (mmol/L) Hexokinase 5.25 (4.05-7.33) 4.00-5.83
Gamma -glutamyl transferase (U/L) γ-glutamyl-carboxy nitroanilide 20 (10-49) < 38§
HDL-cholesterol (mmol/L) Direct, non-immunologic 1.41 (0.67-2.10) 0.8-2.0
Lactate dehydrogenase (U/L) Lactate-pyruvate, UV 164 (123-222) < 247§
Protein (total) (g/L) Biuret 71(67-80) 66-83§
Triglyceride (mmol/L) GPO-PAP 0.84 (0.54-3.01) 0.4-3.5
Urea nitrogen (mmol/L) Urease, UV 4.5 (2.9-7.1) 2.1-6.8
Uric acid (µmol/L) Uricase, PAP 232 (155-411) 130-480
* method-specifi c reference intervals established in-house from analysis of healthy adults (23);
§ reference intervals established by manufacturer (Abbott Diagnostics).
TABLE 2. Methods, T0 (median and interquartile range) values and reference intervals.
TABLE 3. Comparison of tubes with gel and without gel for analytes at room temperature or 4 degrees centigrade according to time 

















































45 44 44 44 43 44 44 44 44
1.3%
(2.3%) (0.0%) (0.0%) (0.0%) (-2.3%) (0.0%) (0.0%) (0.0%) (0.0%)
P=0.806 P=0.138 P=0.372 P=0.495 P=0.083 P=0.145 P=0.224 P=0.233 P=0.124
4°C 44
44 44 44 44 43 43 44 44 44
(0.0%) (0.0%) (0.0%) (0.0%) (-2.3%) (-2.3%) (0.0%) (0.0%) (0.0%)




43 45 44 44 45 44 44 44 44
(-2.3%) (2.3%) (0.0%) (0.0%) (2.3%) (0.0%) (0.0%) (0.0%) (0.0%)
P=0.593 P=0.249 P=0.279 P=0.589 P=0.100 P=0.598 P=0.519 P=0.219 P=0.250
4°C 44
44 45 44 45 44 44 44 44 45
(0.0%) (2.3%) (0.0%) (2.3%) (0.0%) (0.0%) (0.0%) (0.0%) (2.3%)
P=1.000 P=0.406 P=0.124 P=0.578 P=0.490 P=0.030 P=0.113 P=0.084 P=0.406
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67 69 70 67 68 69 65 65 65
6.4%
(-1.5%) (1.5%) (2.9%) (-1.5%) (0.0%) (1.5%) (-4.4%) (-4.4%) (-4.4%)
P=0.727 P=0.932 P=0.632 P=0.108 P=0.357 P=0.518 P=0.124 P=0.001 P=0.001
4°C 68
67 68 68 69 68 69 66 69 69
(-1.5%) (0.0%) (0.0%) (1.5%) (0.0%) (1.5%) (-2.9%) (1.5%) (1.5%)




68 68 67 68 69 70 67 66 66
(-1.5%) (-1.5%) (-2.9%) (-1.5%) (0.0%) (1.5%) (-2.9%) (-4.4%) (-4.4%)
P=0.977 P=0.437 P=0.238 P=0.113 P=0.135 P=0.864 P=0.153 P=0.001 P=0.001
4°C 69
66 68 67 67 68 70 67 67 67
(-4.4%) (-1.5%) (-2.9%) (-2.9%) (-1.5%) (1.5%) (-2.9%) (-2.9%) (-2.9%)





















15 15 15 15 15 15 15 15 14
12%
(0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (-6.7%)
P=0.782 P=0.380 P=0.564 P=0.675 P=0.327 P=0.351 P=0.380 P=0.763 P=0.002
4°C 15
15 15 15 14 15 15 15 16 15
(0.0%) (0.0%) (0.0%) (-6.7%) (0.0%) (0.0%) (0.0%) (6.7%) (0.0%)




15 15 15 15 15 14 16 15 12
(0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (-6.7%) (6.7%) (0.0%) (-20%)
P=0.038 P=0.334 P=0.377 P=0.002 P=0.109 P=0.002 P=0.366 P=0.803 P=0.001
4°C 15
15 16 15 14 16 15 15 14 14
(0.0%) (6.7%) (0.0%) (-6.7%) (6.7%) (0.0%) (0.0%) (-6.7%) (-6.7%)






















15 15 15 14 15 14 16 14 13
5.4 %
(7.1%) (7.1%) (7.1%) (0.0%) (7.1%) (0.0%) (14.3%) (0.0%) (-7.1%)
P=0.132 P=0.006 P=0.005 P=0.739 P=0.317 P= 0.218 P=0.030 P=0.080 P=0.034
4°C 14
15 14 15 16 15 15 15 17 15
(7.1%) (0.0%) (7.1%) (14.3%) (7.1%) (7.1%) (7.1%) (21.4%) (7.1%)




15 16 15 15 15 16 15 15 16
(0.0%) (6.7%) (0.0%) (0.0%) (0.0%) (6.7%) (0.0%) (0.0%) (6.7%)
P=0.236 P=0.285 P=0.026 P=0.315 P=0.739 P=1.000 P= 0.038 P=0.005 P=0.404
4°C 15
15 16 15 16 16 17 16 20 16
(0.0%) (6.7%) (0.0%) (6.7%) (6.7%) (13.3%) (6.7%) (33.3%) (6.7%)
P=0.109 P=0.166 P=0.026 P=0.112 P=0.458 P=0.002 P=0.564 P=0.001 P=0.005
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10.8 10.8 9.9 10.6 10.3 10.6 10.9 11.1 11.6
11.4%
(-1.6%) (-1.6%) (-9.3%) (-3.1%) (-6.2%) (-3.1%) (0.0%) (1.7%) (6.3%)
P=0.001 P=0.001 P=0.001 P=0.001 P=0.001 P=0.001 P=0.007 P=0.136 P=0.589
4°C 10.9
10.4 10.3 10.3 10.4 10.3 10.3 10.3 10.3 11.1
(-4.7%) (-6.2%) (-6.2%) (-4.7%) (-6.2%) (-6.2%) (-6.2%) (-6.2%) (1.7%)




10.3 10.3 9.6 10.3 10.3 9.9 9.9 9.9 9.9
(-6.2%) (-6.2%) (-12.4%) (-6.2%) (-6.2%) (-9.3%) (-9.3%) (-9.3%) (-9.3%)
P=0.005 P=0.001 P=0.001 P=0.003 P=0.001 P=0.001 P=0.009 P=0.030 P=0.010
4°C 10.9
10.6 9.9 9.1 10.8 10.3 10.6 10.6 9.9 12.3
(-3.1%) (-9.3%) (-17.2%) (-1.6%) (-6.2%) (-3.1%) (-3.1%) (-9.3%) (12.5%)













4.46 4.43 4.48 4.58 4.56 4.46 4.53 4.48 4.58
4 %
(0.6%) (0.0%) (1.2%) (3.5%) (2.9%) (0.6%) (2.4%) (1.2%) (3.5%)
P=0.001 P=0.014 P=0.021 P=0.030 P=0.004 P=0.001 P=0.002 P=0.001 P=0.062
4°C 4.40
4.50 4.50 4.50 4.50 4.50 4.50 4.50 4.50 4.50
(1.8%) (1.8%) (0.7%) (1.8%) (2.3%) (2.3%) (1.1%) (1.8%) (1.8%)




4.43 4.48 4.58 4.58 4.46 4.51 4.53 4.56 4.61
(-0.7%) (0.5%) (2.7%) (2.7%) (0.0%) (1.1%) (1.6%) (2.2%) (3.4%)
P=0.771 P=0.012 P=0.001 P=0.001 P=0.002 P=0.005 P=0.001 P=0.001 P=0.001
4°C 4.50
4.50 4.50 4.40 4.50 4.50 4.40 4.50 4.50 4.60
(1.6%) (1.1%) (-0.7%) (0.0%) (0.5%) (-0.7%) (1.1%) (0.0%) (2.7%)














83 84 83 83 83 82 82 92 97
11.5 %
(0.0%) (1.2%) (0.0%) (0.0%) (0.0%) (-1.2%) (-1.2%) (10.8%) (16.9%)
P=0.593 P=0.548 P=0.282 P=0.249 P=0.471 P=0.472 P=0.871 P=0.186 P=0.045
4°C 83
82 83 84 84 83 81 82 83 81
(-1.2%) (0.0%) (1.2%) (1.2%) (0.0%) (-2.4%) (-1.2%) (0.0%) (-2.4%)




83 85 86 85 84 86 85 86 105
(-1.2%) (1.2%) (2.4%) (1.2%) (0.0%) (2.4%) (1.2%) (2.4%) (25%)
P=0.008 P=0.714 P=0.716 P=0.078 P=0.593 P=0.297 P=0.593 P=0.233 P=0.001
4°C 83
82 83 84 84 83 81 82 83 81
(- 1.2%) (0.0%) (1.2%) (1.2%) (0.0%) (-2.4%) (-1.2%) (0.0%) (-2.4%)
P=0.175 P=0.816 P=0.399 P=0.336 P=1.000 P=0.305 P=0.088 P=0.006 P=0.003
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70.7 70.7 70.7 61.9 70.7 70.7 70.7 70.7 70.7
4.0 %
(0.0%) (0.0%) (0.0%) (-12.5%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%)
P=0.317 P=0.705 P=0.102 P=0.705 P=0.655 P=0.655 P=1.000 P=0.655 P=0.102
4°C 70.7
70.7 70.7 70.7 70.7 70.7 70.7 70.7 70.7 70.7
(0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%)




70.7 70.7 70.7 70.7 70.7 70.7 70.7 70.7 70.7
(0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%)
P=0.317 P=0.157 P=0.020 P=0.059 P=0.096 P=0.180 P=0.005 P=1.000 P=0.180
4°C 70.7
70.7 70.7 70.7 70.7 70.7 70.7 70.7 61.9 70.7
(0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (-12.5%) (0.0%)




















19 20 19 20 20 19 19 19 21
10.8 %
(-5%) (0.0%) (-5%) (0.0%) (0.0%) (-5%) (-5%) (-5%) (5%)
P=0.206 P=0.206 P=0.058 P=0.627 P=0.190 P=0.903 P=0.386 P=0.429 P=0.206
4°C 20
19 18 19 19 20 19 20 18 18
(-5%) (-10%) (-5%) (-5%) (0.0%) (-5%) (0.0%) (-10%) (-10%)




20 20 19 19 19 20 19 20 21
(5.3%) (5.3%) (0.0%) (0.0%) (0.0%) (5.3%) (0.0%) (5.3%) (10.5%)
P=0.366 P=0.166 P=0.763 P=0.102 P=0.160 P=0.001 P=0.627 P=0.107 P=0.002
4°C 19
19 18 19 20 20 21 19 20 20
(0.0%) (-5.3%) (0.0%) (5.3%) (5.3%) (10.5%) (0.0%) (5.3%) (5.3%)











5.22 5.27 5.16 5.00 5.22 4.94 4.94 4.88 4.77
2.2 %
(-1.0%) (0.0%) (-2.1%) (-5.3%) (-1.0%) (-6.3%) (-6.3%) (-7.4%) (-9.5%)
P=0.026 P=0.334 P=0.400 P=0.003 P=0.003 P=0.003 P=0.001 P=0.001 P=0.001
4°C 5.27
5.27 5.33 5.27 5.22 5.22 5.16 5.11 5.05 5.00
(0.0%) (1.1%) (0.0%) (-1.1%) (-1.1%) (-2.1%) (-3.0%) (-4.2%) (-5.1%)




4.83 5.05 4.77 4.27 4.22 4.05 3.77 3.33 1.0
(-7.5%) (-3.3%) (-8.6%) (-18.2%) (-19.2%) (-22.4%) (-27.8%) (-36.2%) (-80.8%)
P=0.001 P=0.002 P=0.001 P=0.001 P=0.001 P=0.001 P=0.001 P=0.001 P=0.001
4°C 5.22
4.88 4.77 4.61 4.38 4.27 4.22 4.00 3.84 3.55
(-6.5%) (-8.6%) (-11.7%) (-16.1%) (-18.2%) (-19.2%) (-23.4%) (-26.4%) (-32%)
P=0.001 P=0.001 P=0.001 P=0.001 P=0.001 P=0.001 P=0.001 P=0.001 P=0.001
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1.45 1.42 1.48 1.42 1.48 1.45 1.32 1.40 1.48
5.2 %
(-2.0%) (-4.1%) (0.0%) (-4.1%) (0.0%) (-2.0%) (-10.8%) (-5.4%) (0.0%)
P=0.724 P=0.659 P=0.065 P=0.825 P=0.128 P=0.526 P=0.261 P= 0.003 P=0.975
4°C 1.48
1.45 1.45 1.48 1.45 1.37 1.50 1.40 1.40 1.42
(-2.0%) (-2.0%) (0.0%) (-2.0%) (-7.4%) (-1.4%) (-5.4%) (-5.4%) (-4.1%)




1.42 1.48 1.45 1.50 1.45 1.42 1.35 1.32 1.48
(3.7%) (8.0%) (5.8%) (9.5%) (5.8%) (3.7%) (-1.5%) (-3.7%) (8.0%)
P=0.437 P=0.012 P=0.004 P=0.011 P=0.142 P=0.972 P=0.505 P=0.119 P=0.027
4°C 1.37
1.42 1.32 1.37 1.32 1.35 1.40 1.48 1.24 1.45
(3.7%) (-3.7%) (0.0%) (-3.7%) (-1.5%) (2.2%) (8.0%) (-9.4%) (5.7%)



















166 168 162 158 165 166 165 161 169
4.3 %
(1.2%) (2.4%) (-1.2%) (-3.7%) (0.6%) (1.2%) (0.6%) (-1.8%) (3.1%)
P=0.346 P=0.064 P=0.378 P=0.044 P=0.798 P=0.489 P=0.095 P=0.014 P=0.029
4°C 164
162 164 165 160 162 163 160 159 161
(-1.2%) (0.0%) (0.6%) (-2.4%) (-1.2%) (-0.6%) (-2.4%) (-3.1%) (-1.8%)




159 160 159 162 160 164 159 164 304
(-0.6%) (0.0%) (-0.6%) (1.3%) (0.0%) (2.5%) (-0.6%) (2.5%) (90%)
P=0.864 P=0.063 P=0.600 P=0.394 P=0.593 P=0.284 P=0.269 P=0.648 P=0.001
4°C 160
162 160 161 163 168 165 163 164 201
(1.3%) (0.0%) (0.6%) (1.9%) (5%) (3.1%) (1.9%) (2.5%) (25.6%)













70 70 70 70 70 70 70 70 71
1.2 %
(-1.4%) (-1.4%) (-1.4%) (-1.4%) (-1.4%) (-1.4%) (-1.4%) (-1.4%) (0.0%)
P=0.012 P=0.018 P=0.161 P=0.832 P=0.742 P=0.724 P=0.541 P=0.715 P=0.011
4°C 71
70 70 70 70 71 70 71 69 70
(-1.4%) (-1.4%) (-1.4%) (-1.4%) (0.0%) (-1.4%) (0.0%) (-2.8%) (0.0%)




71 71 70 70 70 70 70 70 74
(0.0%) (0.0%) (-1.4%) (-1.4%) (-1.4%) (-1.4%) (-1.4%) (-1.4%) (4.2%)
P=0.071 P=0.627 P=0.225 P=0.162 P=0.127 P=0.102 P=0.301 P=0.169 P=0.008
4°C 71
70 71 70 70 70 69 71 70 72
(-1.4%) (0.0%) (-1.4%) (-1.4%) (-1.4%) (-2.8%) (0.0%) (-1.4%) (1.4%)
P=0.026 P=0.034 P=0.449 P=0.589 P=0.028 P=0.040 P=0.490 P=0.298 P=0.000
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0.84 0.86 0.87 0.83 0.86 0.87 0.84 0.86 0.88
10.7 %
(1.2%) (3.6%) (4.8%) (0.0%) (2.7%) (4.8%) (1.2%) (3.6%) (6.0%)
P=0.059 P=0.145 P=0.004 P=0.009 P=0.062 P=0.001 P=0.001 P=0.001 P=0.001
4°C 0.83
0.89 0.88 0.91 0.86 0.86 0.83 0.86 0.87 0.89
(7.2%) (6.0%) (9.6%) (3.6%) (3.6%) (0.0%) (3.6%) (4.8%) (7.2%)




0.87 0.87 0.87 0.88 0.88 0.90 0.89 0.90 0.94
(1.2%) (1.2%) (1.2%) (2.3%) (2.3%) (4.7%) (3.5%) (4.7%) (9.3%)
P=0.002 P=0.002 P=0.001 P=0.001 P=0.010 P=0.001 P=0.001 P=0.001 P=0.001
4°C 0.83
0.86 0.87 0.88 0.86 0.87 0.89 0.89 0.88 0.90
(3.6%) (4.8%) (6.0%) (3.6%) (4.8%) (7.2%) (7.2%) (6.0%) (8.4%)














4.29 4.29 3.93 4.29 4.29 4.29 3.93 4.64 4.64
5.5 %
(-6.7%) (-6.7%) (-15.3%) (-6.7%) (-6.7%) (-6.7%) (-15.3%) (0.0%) (0.0%)
P=0.206 P=0.046 P=0.084 P=0.161 P=0.109 P=0.331 P=0.218 P=0.062 P=0.083
4°C 4.64
4.64 4.64 4.64 4.64 4.64 4.29 4.64 5.00 4.64
(0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (-7.8%) (0.0%) (7.8%) (0.0%)




4.29 4.29 4.64 4.64 4.64 4.29 4.64 5.00 5.36
(0.0%) (0.0%) (8.2%) (8.2%) (8.2%) (0.0%) (8.2%) (16.6%) (25%)
P=1.000 P=0.942 P=0.130 P=0.206 P=0.796 P=0.1000 P=0.083 P=0.002 P=0.001
4°C 4.29
4.64 4.29 4.64 4.64 4.64 4.29 4.64 5.00 5.00
(8.2%) (0.0%) (8.2%) (8.2%) (8.2%) (0.0%) (8.2%) (16.6%) (16.6%)













238 250 244 244 250 256 262 274 274
4.9%
(2.6%) (7.8%) (5.2%) (5.2%) (7.8%) (10.3%) (12.9%) (18.1%) (18.1%)
P=0.058 P=0.001 P=0.001 P=0.001 P=0.001 P=0.001 P=0.001 P=0.001 P=0.001
4°C 232
226 232 238 238 232 244 244 250 244
0.003 (0.0%) (2.6%) (2.6%) (0.0%) (5.2%) (5.2%) (7.8%) (5.2%)




238 244 256 244 250 262 256 268 286
(2.6%) (5.2%) (10.3%) (5.2%) (7.8%) (12.9%) (10.3%) (15.5%) (23.3%)
P=0.003 P=0.001 P=0.001 P=0.002 P=0.004 P=0.001 P=0.001 P=0.001 P=0.001
4°C 232
232 232 238 220 226 220 232 238 256
(0.0%) (0.0%) (2.6%) (-5.2%) (-2.6%) (-5.2%) (0.0%) (2.6%) (10.3%)
P=0.157 P=0.053 P=0.014 P=0.001 P=0.010 P=0.763 P=0.672 P=0.002 P=0.001
* without gel.
P<0.006 values were written in bold font. Percentages in parenthesis are bias values of specifi c time points compared to initial value (0.5 h) (% 
change from T0 (0.5-h)).
Bold font indicates samples for which the diff erences exceeded the maximum desirable bias.
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based on clinically meaningful variations, as re-
fl ected by deviation from the current analytical 
quality specifi cations for desirable bias (10). Albu-
min and total protein concentrations did not show 
any diff erence signifi cantly up to 72-h in all 
groups.
Time-course plots for selected analytes that illus-
trate various stability situations are presented in 
Figure 1. Glucose, uric acid, BUN, and HDL were 
found as the least stable tests. Glucose concentra-
tions decreased markedly beginning from the fi rst 
hours of storage especially in plain serum (by more 
than 18% just in one day) at RT. HDL was the least 
stable when stored at room temperature in plain 
serum. BUN and uric acid were stable only in 
chilled serum with gel barrier as long as 30-h. AST 
increased only one or two units up to 48-h of stor-
age in all four groups. The percentage changes in 
total bilirubin were under the clinically meaningful 
variations when stored in serum gel tubes either 
at RT or chilled up to one week (Table 3). There 
were no failures in barrier formation in the gel 
tubes during the study.
FIGURE 1. Time and temperature dependency of glucose, uric 
acid, BUN, HDL-C concentrations and AST activity on storage 
of serum in tube with (gel) and without gel (plain). RT – room 
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Discussion
Contrary to possible expectations, the wide range 
of biochemical analytes that are stored in separa-
tor tubes for several days was more stable than 
had already been believed. The current study 
demonstrates that concentrations of albumin, to-
tal protein, creatinine, cholesterol, triglycerides 
and activities of GGT, ALP, ALT, CK, LD did not diff er 
either in serum separator gel tube or in plain tube 
and can be measured reliably in samples kept at 
RT or at 4 °C for at least three days after centrifuga-
tion. Glucose concentrations decreased with in-
creasing serum-clot contact time in plain tube and 
the rate of decrease was sensitive to temperature 
like previous studies (11,12). This decrease was at-
tributed to glycolytic action of erythrocytes and 
leukocytes (13,14) cited by Tietz (15). The rate of de-
crease may be minimized when refrigerated at 4 °C.
BUN demonstrated a better performance with a 
gel barrier like a previous study (16) where the in-
crease in BUN was attributed to hemoconcentra-
tion in serum plain at both temperatures.
The stability of total bilirubin in gel tubes over time 
demonstrated the effi  ciency of gel barrier regard-
less of the temperature in the current study. Simi-
lar to the study from Heins et al. (17), the concen-
trations of total bilirubin showed a decreasing 
trend stored in plain serum at RT.
In general, uric acid instability was prominent at 
RT like previous studies (17,18), and gel tube had 
no advantages over plain tube.
During the experimental study, creatinine showed 
decreases only in concentrations from 18 to 24-h 
with gel tube at RT, and 48 to 72-h with chilled 
plain tube exceeding the desirable bias; however, 
these 8.8 µmol/L decreases may not be considered 
clinically signifi cant. Similar results were obtained 
by Heins et al. (17). Besides, in contrast to the previ-
ous study (16), we demonstrated that gel tube has 
no advantage over plain tube for creatinine assay.
In the current study, small changes in concentra-
tions were observed for albumin and total protein 
which were outside the maximum desirable bias 
(10). However, the analytical and biological varia-
tions of those analytes are very small, for that rea-
son we considered the changes in concentrations 
as clinically insignifi cant.
Cholesterol and triglycerides were stable up to one 
week in the current study. Similar results were ob-
tained by Boyanton and Blick (18).
For HDL, gel tubes at RT and, plain tubes at 4 ºC 
displayed similar results and were stayed stable up 
to 36-h. However, in plain tube at RT, HDL concen-
trations increased by 8.8% at 12-h to a level that 
exceeded the clinically signifi cant value. O’Keane 
and Cunningham (16) reported non signifi cant 
changes up to 48-h in serum gel and in serum 
plain at RT or at 4 ºC. Heins et al. (17) reported in-
creases in HDL concentrations in plain serum at RT, 
but found as stable at 9 ºC.
Since there are discrepancies between the results 
of other studies and the present study, it might be 
explained by diff erences in analytic methods, by 
diff erent storage temperatures and assay intervals 
as most of them assayed in the same run, however 
in the current study all were assayed at diff erent 
time points like Heins et al. (17).
The enzymes GGT, ALP, CK and ALT were found as 
stable up to 72-h of storage in all groups. Heins et 
al. (17) found the same stability in plain serum up 
to one week at RT except for CK.
LD activity was stable as long as one week in se-
rum gel tube at both temperatures.
The impressive peaks in the activity of LD at one 
week in plain sera may be due to interference of 
hemolysis (19-21) caused by changes in cell perme-
ability, and to the fragility of erythocyte mem-
brane during the prolonged storage. Sodi et al. (22) 
examined the eff ect of sample transportation on 
possible hemolysis, and concluded the advantag-
es of gel barrier tubes over plain tubes. Heins et al. 
(17) also emphasized the instability of LD in whole 
blood.
In this study, AST activity changed only a few units 
despite the marked percentage biases and may 
not be considered as clinically signifi cant as long 
as 48-h of storage in all four groups. Heins et al. 
(17) also noted the stability of AST stayed until one 
week at RT.
For total bilirubin, glucose, BUN, uric acid and LD, 
gel tubes showed enhanced stability compared to 
plain tubes and the stability can be maximized by 
refrigeration at 4 ºC. Practically, gel tubes can be 
preferred for prolonged storage, for protection 
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against possible contamination while aliquoting 
and for possible cell leakage.
There are two limitations that need to be acknowl-
edged regarding the present study. The fi rst limi-
tation concerns the visible detection of the possi-
ble hemolysis. We have not studied the free hemo-
globin concentrations in the sera stored during 
the process. So, we have only attributed the biases 
of LD to the possible hemolysis interference. Be-
sides, the evaluation of the storage conditions 
were done on a defi ned analyzer with its corre-
sponding reagents with the samples stored in de-
fi ned tube types. Therefore, the results of the cur-
rent study might not be universally reproducible 
with other testing systems for the evaluation of 
the stabilities of samples stored for a time period 
before analysis.
In conclusion, in the current study, we have shown 
that the concentrations of many analytes in sera in 
separator tube with gel or without gel did not 
show any signifi cant changes even at RT as long as 
three days. Therefore, those mentioned analytes 
may be measured reliably in mailed blood sam-
ples. However it is important to note that, in hotter 
climates, (higher than the defi ned room tempera-
ture in this study), if the samples needed to be 
stored for long periods until analysis, gel tubes 
and storage with cold packs may be a better op-
tion.
Potential confl ict of interest
None declared.
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Ispitivanje stabilnosti biokemijskih analita u serumskim epruvetama s ili bez 
gela za odvajanje u različitim uvjetima pohranjivanja
Sažetak
Uvod: Sakupljeni i transportirani uzorci krvi često su prije same analize izloženi različitim izvananalitičkim čimbenicima. Cilj ovog ispitivanja 
bio je utvrditi stabilnost analita u epruvetama za odvajanje seruma s gelom i u običnim epruvetama koje su nakon centrifugiranja bile izložene 
širokom rasponu temperatura i vremena pohranjivanja.
Materijali i metode: U istraživanju je sudjelovalo 15 dobrovoljaca od kojih je sakupljena venska krv u četiri epruvete, dvije s gelom za razdva-
janje seruma, a dvije bez gela. Nakon analize uzoraka te određivanja početnih vrijednosti 30 minuta nakon uzimanja krvi, svi su uzorci pohranjeni 
na 4 °C ili 24 °C tijekom 6, 12, 18, 24, 30, 36, 48, 72 sata i jedan tjedan. U svakom je uzorku određena koncentracija 16 biokemijskih parametara. 
Varijacije ispod željene sustavne pogreške smatrane su klinički neznačajnima.
Rezultati: Trećeg je dana većina analita ostala stabilnima uključujući albumin, protein, kreatinin, kolesterol, trigliceride, gama-glutamil-trans-
ferazu (GGT), alkalnu fosfatazu (ALP), kreatin-kinazu (CK), laktat-dehidrogenazu (LD) bez obzira na vrstu epruvete. Stabilnost glukoze, pohran-
jene u epruveti bez gela (u čistom serumu) značajno je smanjenja (P=0,001) već nakon prvih sati pohranjivanja. Najveća je stabilnost primjećena 
kod analita pohranjenih na 4 °C u epruvetama s gelom i to kod glukoze, ukupnog bilirubina, ureje (BUN) i mokraćne kiseline. Aktivnost aspar-
tat-aminotransferaze (AST) značajno je porasla (P = 0,002) kod uzoraka pohranjenih do 48 sati, međutim sustavna pogreška nije bila klinički 
značajna. Koncentracija HDL kolesterola bila je stabilna u epruvetama s gelom na 24 °C te u običnim epruvetama na 4 °C do 36 sati.
Zaključak: Epruvete za odvajanje seruma s ili bez gela mogu se primjenjivati naizmjenično za 11 analita ohlađenih na 4 °C ili na temperaturi od 
24 °C, dok kod određivanja koncentracije glukoze, HDL kolesterola, mokraćne kiseline, uree i aktivnosti AST trebaju postojati neka ograničenja.
Ključne riječi: uzorkovanje; stabilnost enzima; pohranjivanje; temperatura
